Physician profile
Perminder J S Bhatia
NPI 1013002328
$279,220.44
in general payments reported to CMS, 2019-2025
100 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $28K · 2021: $21K · 2022: $23K · 2023: $30K · 2024: $77K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Food and Beverage: $19K · Travel and Lodging: $18K · Consulting Fee: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Honoraria: $14K · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,298.00 |
| Food and Beverage | $19,479.67 |
| Travel and Lodging | $17,686.46 |
| Consulting Fee | $16,780.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,220.00 |
| Honoraria | $13,838.00 |
| Education | $313.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,193.93 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $33,983.98 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $31,986.99 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $30,349.91 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $29,100.92 | 2019-2025 | Rexulti, Nuedexta |
| Sk Life Science, INC. | $28,459.31 | 2020-2025 | Xcopri |
| Allergan, INC. | $15,130.77 | 2019-2022 | |
| Axsome Therapeutics, INC. | $14,361.13 | 2022-2025 | Symbravo, Auvelity |
| Acorda Therapeutics, INC | $12,608.11 | 2019-2023 | Inbrija |
| Argenx US, INC. | $5,632.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Boston Scientific Corporation | $3,465.80 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $3,354.24 | 2020-2021 | |
| Ucb, INC. | $3,116.71 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Ipsen Innovation | $3,041.62 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $2,453.69 | 2022 |
Show all 94 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,338.79 | 2019-2025 | |
| Banner Life Sciences, LLC | $2,048.08 | 2020-2024 | |
| Mdd US Operations, LLC | $1,928.98 | 2023-2025 | Myobloc, Gocovri, Gocovri |
| Livanova USA, INC. | $1,927.72 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $1,740.19 | 2019-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $1,491.30 | 2020-2022 | |
| Biogen, INC. | $1,484.53 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Neurocrine Biosciences, INC. | $1,112.63 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $1,048.91 | 2019-2025 | Mavenclad |
| Genentech USA, INC. | $801.48 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Ani Pharmaceuticals, INC. | $665.62 | 2022-2025 | Purified Cortrophin Gel |
| Amneal Pharmaceuticals LLC | $646.70 | 2019-2025 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Kyowa Kirin, INC. | $624.46 | 2019-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $592.25 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $501.62 | 2019-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $479.78 | 2020-2025 | Wakix |
| Mallinckrodt Hospital Products INC. | $465.23 | 2020-2025 | Acthar |
| Amgen INC. | $461.34 | 2019-2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $455.68 | 2019-2025 | Hyqvia, Gammagard, Trintellix |
| Sunovion Pharmaceuticals INC. | $446.18 | 2019-2022 | |
| Neurelis, INC. | $437.55 | 2021-2025 | Valtoco |
| Genzyme Corporation | $409.29 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $361.12 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.92 | 2019-2025 | Relistor |
| Csl Behring | $303.20 | 2019-2025 | Hizentra |
| Pfizer INC. | $281.66 | 2019-2025 | |
| Ge Healthcare | $278.36 | 2019-2025 | |
| Octapharma USA, INC. | $270.49 | 2023-2025 | Panzyga |
| Celgene Corporation | $262.38 | 2020-2025 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $247.23 | 2019-2025 | Dysport, Sohonos |
| Avanir Pharmaceuticals, INC. | $238.10 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $215.91 | 2021-2025 | Xeomin, Inbrija |
| Catalyst Pharmaceuticals, INC. | $205.99 | 2019-2024 | Firdapse, Fycompa |
| Astrazeneca Pharmaceuticals Lp | $196.78 | 2021-2024 | Andexxa |
| Horizon Therapeutics Plc | $163.76 | 2020-2023 | Uplizna |
| Jazz Pharmaceuticals INC. | $161.20 | 2024-2025 | |
| Abbott Laboratories | $161.04 | 2023-2024 | Amplatzer Talisman, Proclaim |
| Virtus Pharmaceuticals LLC | $142.54 | 2023-2025 | Levorphanol Tartrate |
| Sumitomo Pharma America, INC. | $133.31 | 2023-2024 | Aptiom |
| Adamas Pharmaceuticals, INC. | $125.84 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $117.94 | 2020-2025 | Amvuttra |
| Neuropace, INC. | $114.39 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $100.85 | 2019-2024 | Ztlido |
| Medtronic, INC. | $97.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.96 | 2023 | |
| Tg Therapeutics, INC. | $90.31 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $86.95 | 2020-2021 | |
| Janssen Biotech, INC. | $84.67 | 2025 | |
| Upsher-Smith Laboratories LLC | $82.51 | 2020-2023 | |
| Vanda Pharmaceuticals INC. | $78.19 | 2024-2025 | Ponvory |
| Arbor Pharmaceuticals, INC. | $76.47 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $62.72 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $58.70 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $58.06 | 2022-2023 | Trudhesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.33 | 2023 | |
| Grifols USA, LLC | $39.93 | 2022-2025 | Gamunex-C |
| Nevro Corp. | $37.08 | 2022-2023 | Senza |
| Zogenix INC. | $36.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $35.71 | 2024 | Horizant |
| Tanabe Pharma America, INC. | $33.55 | 2019-2024 | |
| Biodelivery Sciences International, INC. | $33.19 | 2021 | |
| Merz North America, INC. | $32.58 | 2019 | |
| Aucta Pharmaceuticals, INC. | $26.60 | 2025 | Motpoly Xr |
| Greenwich Biosciences, INC. | $26.39 | 2021 | |
| Cycle Pharmaceuticals INC | $26.09 | 2025 | Tascenso Odt, Bafiertam |
| Mallinckrodt Enterprises LLC | $24.61 | 2019 | |
| Insightec,INC | $23.78 | 2022 | |
| Vertical Pharmaceuticals, LLC | $21.24 | 2019 | |
| Akcea Therapeutics, INC. | $19.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.94 | 2019 | |
| Zyla Life Sciences, INC. | $17.19 | 2020 | |
| Ibsa Pharma INC. | $16.76 | 2020 | |
| Grt US Holding, INC. | $16.58 | 2022 | |
| Averitas Pharma INC. | $16.38 | 2024 | Qutenza |
| Aquestive Therapeutics, INC. | $15.46 | 2021 | |
| Janssen Scientific Affairs, LLC | $14.25 | 2025 | |
| Life Molecular Imaging Ltd | $14.03 | 2022 | |
| Redhill Biopharma INC. | $13.20 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $12.20 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,818.95 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perminder Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.